“We are extremely pleased to extend our relationship with the FDA and the Harvard Pilgrim Health Care Institute,” said Michael Sullivan, Director of U.S. ![]() “This new contract provides FDA and the HPHCI team access to TriNetX’s growing network of EMRs that we expect to leverage for multiple purposes in the coming months and years.” “We recognize the importance of TriNetX to achieving the goals we have set for the Sentinel program, in particular incorporating EMR data into Sentinel to support FDA needs,” said Jeffrey Brown, PhD, from the Department of Population Medicine at the Harvard Pilgrim Health Care Institute and Harvard Medical School. Sentinel is the FDA’s largest RWD platform for conducting post market safety analyses. Sentinel is one of the FDA’s premier evidence-generation platforms and has become a core feature of the agency’s post-market safety system. We are excited about this partnership which aims to further support FDA’s real-world data and evidence initiatives.” “Being able to directly and interactively query TriNetX data in real-time and to answer questions quickly provides the agency with a unique capability and is playing a role in FDA’s response to the COVID-19 pandemic. “There is clearly a need for a large, frequently refreshed, and up-to-date EMR dataset to support FDA’s response to COVID-19,” said Jennifer Stacey, Vice President, Clinical Sciences at TriNetX. TriNetX is working closely to support the Sentinel Initiative, a national data network set up by the FDA and led by HPHCI to monitor the safety of regulated medical products. ![]() The agency’s epidemiologists are already directly leveraging the TriNetX platform to access RWD and conduct in-depth analyses to monitor the use of critical drugs for COVID-19 patients in an effort to monitor potential drug shortages and to better understand the natural history of the disease. The contract builds on TriNetX’s growing relationship with the FDA. network for the FDA’s Office of Surveillance and Epidemiology (OSE) and the Sentinel Operations Center (SOC) led by the Harvard Pilgrim Health Care Institute (HPHCI). FDA, through its Sentinel Program, is licensing the full TriNetX analytics suite that provides direct access to de-identified real-world data (RWD) in the TriNetX U.S. FDA Staff Gain Rapid Clinical Insight Capability Leveraging the TriNetX Real-World Data and Analytics PlatformĬambridge, MA, JTriNetX, the global health research network that revolutionizes clinical research and enables discoveries through the generation of real-world evidence (RWE), today announced the signing of an agreement with the FDA Sentinel Program.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |